title: Aflibercept, ipilimumab, and vemurafenib.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.forename: Angelica Y
authors.initials: AY
authors.lastname: Au
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000074324:Ipilimumab; D008268:Macular Degeneration / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics; D050505:Mutant Proteins / Q000037:antagonists & inhibitors; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; D007211:Indoles; D000074324:Ipilimumab; D050505:Mutant Proteins; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; C533178:aflibercept; D000077484:Vemurafenib; D040262:Receptors, Vascular Endothelial Growth Factor; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf